Market Newsdesk

New Gold Provides COVID-19 Update at Rainy River Mine

TORONTO–(BUSINESS WIRE)–April 21, 2021 — New Gold Inc. (“New Gold” or the “Company”) (TSX and NYSE American: NGD) today announces that three employees at the Rainy River Mine in northwestern Ontario received positive COVID-19 test results. An additional seven employees have tested non-negative with the in-house PCR device and the mine is awaiting confirmation from the Northwestern Health Unit (“NWHU”). All affected individuals have been isolated and are no longer on site.

“The Company has a comprehensive COVID-19 response plan in place and the health and safety of our workforce, and our communities remain our number one concern. We will support all initiatives that align with that objective,” stated Renaud Adams, President and CEO.

Operations continue at the Rainy River Mine and the Company will continue to closely work with the NWHU and monitor the situation. The Company will provide updates as appropriate.

The Company’s COVID-19 measures are in place to mitigate and limit the spread of COVID-19 and protect the well-being of its employees, contractors, their families, local communities, and other stakeholders. New Gold has and continues to follow the Public Health guidance and directives of federal, provincial, and regional authorities in respect of general and mine site-specific protocols and is working in close partnership with its medical service provider and NWHU.

The Rainy River Mine will continue to work with surrounding Indigenous and local communities to implement and coordinate actions that will reduce the risk of the spread of COVID-19.

Further information on the Company’s response to COVID-19 is available via the following link: https://www.newgold.com/covid-19/

Xtrackers S&P 500 ESG ETF Breaks Through USD 500 Million in Assets

NEW YORK–(BUSINESS WIRE)–
DWS’s Xtrackers S&P 500 ESG ETF (NYSE Arca: SNPE), has broken through USD 500 million in assets as investor money continues to move into the product amid rising investor interest in environmental, social and governance (ESG) ETFs.

The increasing popularity of the product, which currently registers USD 545 million in assets under management (AUM)¹, is driven by investor demand for sustainable solutions to supplement their investment strategy, while also seeking to generate attractive returns.

DWS, one of the world’s leading asset managers, is also one of the largest ESG ETF providers globally, with $14bn AUM in dedicated ESG ETFs. The firm’s Xtrackers suite of funds has an AUM of $21bn in the U.S., and $178bn globally.²

The Xtrackers S&P 500 ESG ETF tracks large US stocks, with similar risk and return characteristics to the S&P 500 Index, but with a weighting towards companies with the strongest ESG characteristics relative to sector peers. It has a net expense ratio of 0.10% (0.11% gross).³

Amanda Rebello, DWS Head of Passive Sales, US onshore, commented: “Momentum into Xtrackers ETFs, and in particular into our ESG suite, continues. We expect to see even higher levels of investor interest with the Biden administration’s focus on climate policy, including the Paris Agreement, and also as the economy continues to recover from the impact of the pandemic.”

Listed options on SNPE began trading on the NYSE last month, providing an additional route for investors to gain exposure to the product, as well as potentially hedge existing positions.

The Xtrackers ESG range spans US- and international, as well as corporate- and emerging market bond exposures, and was awarded ‘ETF Suite of the Year’ at Fund Intelligence’s Mutual Fund Industry and ETF Virtual Awards 2020.⁴ The Xtrackers ESG range was expanded earlier this year with the launch, in February, of the Xtrackers S&P MidCap 400 ESG ETF (NYSE Arca: MIDE) and Xtrackers S&P SmallCap 600 ESG ETF (NYSE Arca: SMLE).

¹ Source: DWS, 13 April 2021

² Source: DWS, Xtrackers AUM of $14bn in dedicated ESG ETFs; $21bn in the U.S.; and $178bn globally, current as of April 15, 2021.

³ The Advisor has contractually agreed through December 17, 2021 to waive its fees and/or reimburse fund expenses to the extent necessary to prevent the operating expenses of the fund (excluding interest expense, taxes, brokerage expenses, distribution fees or expenses, litigation expenses and other extraordinary expenses) from exceeding 0.10% of the fund’s average daily net assets. This agreement may only be terminated by the fund’s Board (and may not be terminated by the Advisor) prior to that time.

⁴ Xtrackers ESG ETF product portfolio was named ‘ETF Suite of the Year’ at the 27th annual Fund Intelligence’s Mutual Fund Industry and ETF Virtual Awards 2020. These industry awards are meant to recognize people and organizations whose excellence, achievements and contributions to the mutual fund industry have stood out. In addition, Xtrackers MSCI USA ESG Leaders Equity ETF (USSG) won the ‘Newcomer ESG/Impact ETF of the Year’ accolade. For more information on methodology and judging process for the awards, please visit: https://mutualfundindustryawards.awardstage.com/#!/home-of0eb3nc9stuglc7mkd. The Top ETF Suite award is given to the most successful suite of ETFs as determined by a combination of several elements, such as flows, performance, innovation and fund objectives.

About DWS Group

DWS Group (DWS) is one of the world’s leading asset managers with USD 969bn of assets under management (as of 31 December 2020). Building on more than 60 years of experience, it has a reputation for excellence in Germany, Europe, the Americas and Asia. DWS is recognized by clients globally as a trusted source for integrated investment solutions, stability and innovation across a full spectrum of investment disciplines.

We offer individuals and institutions access to our strong investment capabilities across all major asset classes and solutions aligned to growth trends. Our diverse expertise in Active, Passive and Alternatives asset management – as well as our deep environmental, social and governance focus – complement each other when creating targeted solutions for our clients. Our expertise and on-the-ground-knowledge of our economists, research analysts and investment professionals are brought together in one consistent global CIO View, which guides our investment approach strategically.

DWS wants to innovate and shape the future of investing: with approximately 3,500 employees in offices all over the world, we are local while being one global team. We are investors – entrusted to build the best foundation for our clients’ future.

IMPORTANT INFORMATION

ETF shares are not individually redeemable, and owners of shares may acquire those shares from the Fund, or tender such shares for the redemption to the Fund, in Creation Units only.

Consider each fund’s investment objectives, risk factors, and charges and expenses before investing. This and other important information can be found in the fund’s prospectus, which may be obtained by calling 1-855-DBX-ETFS (1-855-329-3837) or by viewing or downloading a prospectus at www.Xtrackers.com. Please read it carefully before investing.

Xtrackers ETFs are managed by DBX Advisors LLC (the Advisor), and distributed by ALPS Distributors, Inc. (ALPS). The Advisor is a wholly owned subsidiary of DWS Group GmbH & Co. KGaA, and is not affiliated with ALPS.

Xtrackers S&P 500 ESG ETF: Investing involves risk, including the possible loss of principal. Investing in securities that meet ESG criteria may result in the fund forgoing otherwise attractive opportunities, which may result in underperformance when compared to funds that do not consider ESG factors. Stocks may decline in value. Stocks of medium-sized companies involve greater risk than securities of larger, more-established companies. Funds investing in a single industry, country or in a limited geographic region generally are more volatile than more diversified funds. Various factors, including costs, cash flows and security selection, may cause the fund’s performance to differ from that of the index. Performance of the fund may diverge from that of the Underlying Index due to operating expenses, transaction costs, cash flows, use of sampling strategies or operational inefficiencies. This fund is non-diversified and can take larger positions in fewer issues, increasing its potential risk. An investment in this fund should be considered only as a supplement to a complete investment program for those investors willing to accept the risks associated with the fund. Please read the prospectus for more information.

Xtrackers S&P MidCap 400 ESG ETF: ESG criteria in a fund’s investment strategy does not guarantee a return or protect against a loss. This fund is new and has limited operating history. Investing involves risk, including the possible loss of principal. Stocks may decline in value. Stocks of medium‐sized companies involve greater risk than securities of larger, more‐established companies. Performance of the Fund may diverge from that of the Underlying Index due to operating expenses, transaction costs, cash flows, use of sampling strategies or operational inefficiencies. This fund is non‐diversified and can take larger positions in fewer issues, increasing its potential risk. Investing in securities that meet ESG criteria may result in the fund forgoing otherwise attractive opportunities, which may result in underperformance when compared to funds that do not consider ESG factors. An investment in this fund should be considered only as a supplement to a complete investment program for those investors willing to accept the risks associated with the fund. Please read the prospectus for more information.

Xtrackers S&P SmallCap 600 ESG ETF: ESG criteria in a fund’s investment strategy does not guarantee a return or protect against a loss. This fund is new and has limited operating history. Investing involves risk, including the possible loss of principal. Stocks may decline in value. Small company stocks tend to be more volatile than medium‐sized or large company stocks. Performance of the Fund may diverge from that of the Underlying Index due to operating expenses, transaction costs, cash flows, use of sampling strategies or operational inefficiencies. This fund is non‐diversified and can take larger positions in fewer issues, increasing its potential risk. Investing in securities that meet ESG criteria may result in the fund forgoing otherwise attractive opportunities, which may result in underperformance when compared to funds that do not consider ESG factors. An investment in this fund should be considered only as a supplement to a complete investment program for those investors willing to accept the risks associated with the fund. Please read the prospectus for more information.

Past performance is no guarantee of future results.

This press release shall not constitute an offer to sell or a solicitation to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer or solicitation or sale would be unlawful prior to registration or qualification under the laws of such state or jurisdiction.

Certain statements contained in this release may be forward-looking in nature. These include all statements relating to plans, expectations, and other statements that are not historical facts and typically use words like “expect,” “anticipate,” “believe,” “intend,” and similar expressions. Such statements represent management’s current beliefs, based upon information available at the time the statements are made, with regard to the matters addressed. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in, or implied by, such statements. Management does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. The following factors, among others, could cause actual results to differ materially from forward-looking statements: (i) the effects of adverse changes in market and economic conditions; (ii) legal and regulatory developments; and (iii) other additional risks and uncertainties, including public health crises (including the recent pandemic spread of the novel coronavirus), war, terrorism, trade disputes and related geopolitical events.

NOT FDIC/ NCUA INSURED • MAY LOSE VALUE • NO BANK GUARANTEE

NOT A DEPOSIT • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY

The brand DWS represents DWS Group GmbH & Co. KGaA and any of its subsidiaries such as DWS Distributors, Inc. which offers investment products or DWS Investment Management Americas, Inc. and RREEF America L.L.C. which offer advisory services.

R- 082722-1 (4/21) DBX004882 (4/22)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005344/en/

Kenny Juarez

DWS

Phone: 1-212-454-9994

E-Mail: [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Logo

Docebo to Host First Quarter Fiscal 2021 Conference Call

TORONTO–(BUSINESS WIRE)–Docebo Inc. (Nasdaq:DCBO; TSX:DCBO) (“Docebo” or the “Company“), a leading AI-Powered Learning Platform, announced today that it will hold a conference call to discuss its first quarter fiscal year 2021 results on Thursday, May 13, 2021 at 8:00 a.m. (ET). The call will be hosted by Claudio Erba, Chief Executive Officer, and Ian Kidson, Chief Financial Officer, followed by a question and answer period. Docebo will report its financial results in the morning prior to the call.

First Quarter Fiscal Year 2021 Conference Call Details:

Date:		Thursday, May 13, 2021
Time:		8:00 a.m. (ET)
Dial in number:		(416) 764-8688 or 1-888-390-0546
		Italy: 800797692
		UK: 08006522435
Live webcast:		https://bit.ly/3mTMn5p
		Webcast will be archived for 90 days and available at http://investors.docebo.com
Replay:		(416) 764-8677 or 1-888-390-0541
		Available until May 20, 2021
Replay passcode:		820926

About Docebo

Docebo is redefining the way enterprises learn by applying new technologies to the traditional corporate learning management system market. Docebo provides an easy-to-use, highly configurable learning platform with end-to-end capabilities designed to make customers, partners, and employees love their learning experience.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005341/en/

Dennis Fong, Investor Relations

(416) 283-9930

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Internet Data Management Other Technology Technology Software

MEDIA:

Logo

Lufax to Announce First Quarter 2021 Financial Results on April 26, 2021

SHANGHAI–(BUSINESS WIRE)–
Lufax Holding Ltd (“Lufax” or the “Company”) (NYSE: LU), a leading technology-empowered personal financial services platform in China, today announced that it plans to release its first quarter 2021 financial results after the market closes on Monday, April 26, 2021.

The Company’s management will hold an earnings conference call at 9:00 P.M. U.S. Eastern Time on Monday, April 26, 2021 (9:00 A.M. Beijing Time on Tuesday, April 27, 2021) to discuss the financial results. For participants who wish to join the call, please complete online registration using the link provided below in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the Direct Event passcode, and a unique access PIN, which can be used to join the conference call.

Registration Link: http://services.choruscall.ca/DiamondPassRegistration/register?confirmationNumber=544437&linkSecurityString=bc690d06

A replay of the conference call will be accessible through May 3, 2021 (dial-in numbers: +1 (800) 319-6413 or +1 (604) 638-9010; replay access code: 544437). A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.lufaxholding.com.

About Lufax

Lufax Holding Ltd is a leading technology-empowered personal financial services platform in China. Lufax Holding Ltd primarily utilizes its customer-centric product offerings and offline-to-online channels to provide retail credit facilitation services to small business owners and salaried workers in China as well as tailor-made wealth management solutions to China’s rapidly growing middle class. The Company has implemented a unique, capital-light, hub-and-spoke business model combining purpose-built technology applications, extensive data, and financial services expertise to effectively facilitate the right products to the right customers.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005405/en/

Investor Relations

Lufax Holding Ltd

Email: [email protected]

ICR Inc.

Jack Wang

Tel: +1 (646) 308-0546

Email: [email protected]

KEYWORDS: China Asia Pacific

INDUSTRY KEYWORDS: Finance Banking Professional Services Technology Software

MEDIA:

Posted on April 21, 2021 8:03 am

Renesas and SiFive Partner to Jointly-Develop Next-Generation High-End RISC-V Solutions for Automotive Applications

Renesas and SiFive Partner to Jointly-Develop Next-Generation High-End RISC-V Solutions for Automotive Applications

SiFive to License Industry-Leading RISC-V Core IP Portfolio to Renesas

TOKYO & SAN MATEO, Calif.–(BUSINESS WIRE)–
Renesas Electronics Corporation (TSE:6723), a premier supplier of advanced semiconductor solutions, and SiFive, Inc., the industry leader in RISC-V processors and silicon solutions, today announced a strategic partnership to jointly develop next-generation, high-end RISC-V solutions for automotive applications. The partnership will also include SiFive licensing the use of their RISC-V core IP portfolio to Renesas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005304/en/

“RISC-V is an important element in providing additional capabilities and options for new and existing customers,” said Takeshi Kataoka, Senior Vice President, General Manager of Automotive Solution Business Unit at Renesas. “We are very excited to work with SiFive as their lead partner to develop next-generation semiconductor solutions through the collaboration of our accumulated expertise in the automotive field, and SiFive’s high-end RISC-V technologies.”

“We are excited to collaborate with Renesas to develop next-generation automotive solutions powered by the SiFive Intelligence platform,” said Patrick Little, Chairman and CEO, SiFive. “Our roadmap of advanced, high-performance RISC-V processor cores and AI accelerators will deliver significant core performance increases with the capabilities needed to meet Automotive application requirements, along with enhanced AI capabilities to power scalable, workload-accelerated solutions.”

Renesas provides automotive solutions including ADAS, Autonomous Driving (AD), Electric Vehicles (EV), and Connected Gateway (CoGW) to customers all over the world by utilizing its diverse portfolio of industry-leading microcontrollers (MCUs) and system-on-chips (SoCs), as well as analog and power products. With a safe, comfortable, and environmentally-conscious society of future mobility in mind, Renesas is exploring the use of next-generation, high-performance RISC-V cores optimized for automotive applications to expand high-end SoC and MCU development capabilities to continue providing innovative and trusted automotive solutions to customers worldwide.

The SiFive Intelligence platform, based on SiFive RISC-V Vector processors with AI ISA extensions, features a differentiated software toolchain to enable the development of scalable solutions for AI and ML applications. SiFive RISC-V processors are pre-integrated with advanced trace, debug, and security solutions compatible with industry tools to simplify heterogeneous integration and migration. The SiFive RISC-V portfolio is silicon-proven and available in leading and advanced manufacturing foundries, offering flexibility for customers and partners.

About Renesas Electronics Corporation

Renesas Electronics Corporation (TSE: 6723) delivers trusted embedded design innovation with complete semiconductor solutions that enable billions of connected, intelligent devices to enhance the way people work and live. A global leader in microcontrollers, analog, power, and SoC products, Renesas provides comprehensive solutions for a broad range of automotive, industrial, Infrastructure, and IoT applications that help shape a limitless future. Learn more at renesas.com. Follow us on LinkedIn, Facebook, Twitter, and YouTube.

About SiFive

SiFive is the leading provider of processor cores, AI accelerators, and SoC IP to enable domain-specific designs based on the open RISC-V instruction set architecture specification. SiFive offers scalable, configurable processor cores pre-integrated with security, trace, and debug features for workload-specific accelerator designs. Founded by the inventors of RISC-V, SiFive has design centers worldwide and backing from Sutter Hill Ventures, SK hynix, Qualcomm Ventures, Western Digital, Intel Capital, Spark Capital, Osage University Partners, and Prosperity7 Ventures. For more information, please visit www.sifive.com.

Stay current with the latest SiFive updates via Facebook, Instagram, LinkedIn, Twitter, and YouTube.

(Remarks) All names of products or services mentioned in this press release are trademarks or registered trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005304/en/

Kyoko Okamoto

Renesas Electronics Corporation

+ 81-3-6773-3001 (Japan)

[email protected]

Hilary Livingston Castle

INK Communications for SiFive

203.858.7259

[email protected]

KEYWORDS: California United States Japan North America Asia Pacific

INDUSTRY KEYWORDS: Data Management Semiconductor Consumer Electronics Automotive Technology Performance & Special Interest Hardware

MEDIA:

Logo

Logo

DXC Technology to Help First Horizon Bank Optimize Commercial Credit Card Processing and Provide Roadmap for Future Growth of Overall Program

Leading U.S. bank expected to increase commercial card processing volume by 150%, enhance fraud and security protection and leverage a new digital roadmap for future growth

TYSONS, Va.–(BUSINESS WIRE)–DXC Technology (NYSE: DXC) announced today that First Horizon Bank has selected DXC to provide commercial credit card processing services to its treasury management customers. Using DXC’s modernized, end-to-end commercial card infrastructure, First Horizon anticipates volume growth of up to 150% by leveraging DXC’s technology suite of competitive and innovative products. First Horizon will also take advantage of DXC’s dedicated 24/7/365 commercial card support team, which will enhance the customer experience while providing improved fraud and security protection.

With the July 2020 merger of IBERIABANK and First Horizon, the combined company’s increased scale and diversified business model necessitated a consolidation under a single commercial card services provider. DXC, the card servicer for IBERIABANK for more than a decade, was selected over one of its top competitors to help the new company (now operating under the First Horizon name) with its transformation journey.

“We are very impressed with DXC’s ability to deliver nearly 50 different analytics, enhanced fraud and security protection and optimized processes that will help build our overall operations to scale so that our clients can experience a best-in-class product offering,” said Starr Williams, Commercial Card Director, First Horizon Bank. “During IBERIABANK’s long-standing relationship with DXC, the card processing team has consistently shown their commitment to the commercial card industry with the stellar services they deliver to the bank and our clients. These factors weighed heavily in our decision to extend our relationship.”

With this expanded relationship, First Horizon will benefit from these additional DXC Business Process Services:

• Client-branded customer service and fraud call centers staffed 24/7/365
• Fraud monitoring, analysis and new strategy implementations in near-real time
• Back-office support for charge-back processing, settlement and data entry
• Client-facing card management platform, including real-time access to transaction activity, creation and cancellation of accounts, cardholder maintenance and reporting

“First Horizon’s confidence in the selection of DXC for these mission-critical process services reflects the ‘new DXC’, which is focused on our customers and our people, as we continue to execute our transformation journey,” said Jim Brady, VP and General Manager, Americas, DXC. “We listened carefully to First Horizon’s needs and proposed how to best extend our capabilities across the Enterprise Technology Stack to achieve their goals, elevate customer experiences and deliver future operations value.”

DXC’s business process services are focused on helping our customers deliver better business results through service excellence, process innovation and value through data insights. For additional information, visit DXC Business Process Services.

About DXC Technology

DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy the Enterprise Technology Stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology.

About First Horizon

First Horizon National Corp. (NYSE:FHN), with $83 billion in assets, is a leading regional financial services company, dedicated to strengthening the lives of its associates, clients, shareholders, and communities. Headquartered in Memphis, TN, the banking subsidiary First Horizon Bank operates nearly 500 bank locations in 12 states across the Southeast. With more than 288 years of combined First Horizon Bank and IBERIABANK financial experience, the Company and its subsidiaries offer commercial, private banking, consumer, small business, wealth and trust management, retail brokerage, capital markets, fixed income, mortgage, and title insurance services. First Horizon is recognized as one of the nation’s best employers by Fortune and Forbes magazines and a Top 10 Most Reputable U.S. bank. More information is available at www.FirstHorizon.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005197/en/

Frank Hurteau, Corporate Media Relations, +1.703.582.4665, [email protected]

John Sweeny, Investor Relations, +1.908.315.3665, [email protected]

Lori Chase, First Horizon Bank, SVP & Public Relations Director, +770.861.2786, [email protected]

KEYWORDS: Virginia United States North America

INDUSTRY KEYWORDS: Technology Mobile/Wireless Finance Security Banking Professional Services Software Internet Data Management

MEDIA:

Logo

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

– New combination trial of an RNA-targeted therapeutic candidate and an HBV immunotherapeutic candidate aimed at delivering a functional cure for chronic hepatitis B infection –

DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection. This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005339/en/

The multi-center, randomized, open-label study is designed to evaluate the safety and efficacy of BRII-835 (VIR-2218) compared to the combination of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with and without interferon-alpha as a co-adjuvant. Both agents have demonstrated proof of mechanism in HBV patients (NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study). Brii Bio has led the design and implementation of this functional cure proof-of-concept study with the support of VIR and VBI, and is the sponsor of the Phase 2 study (NCT04749368). It will be conducted at sites in Australia, China, Taiwan, Hong Kong Special Administrative Region of China, South Korea, New Zealand, Singapore, and Thailand.

Li Yan, M.D., Ph.D., chief medical officer of Brii Bio, said: “Sustained seroclearance of HBV surface antigen, also known as a functional cure, occurs rarely in the natural history of HBV infection or during the current standard of care treatment. We believe that both viral antigen knockdown with BRII-835 (VIR-2218) and sustained induction of HBV-specific host immune responses by BRII-179 (VBI-2601) are required to remove viral immunosuppression and subsequently break immune tolerance. The combination of these two agents is a step toward developing a functional cure for HBV.”

Phil Pang, M.D., Ph.D., chief medical officer of Vir, said: “This new combination trial represents an important addition to our HBV portfolio approach of combining VIR-2218 with various immunomodulators, including pegylated interferon alpha, VIR-3434 and with a TLR8 agonist, via our previously announced collaboration with Gilead. We look forward to determining if such combinations can stimulate an effective immune response that may result in a finite duration of treatment.”

Francisco Diaz-Mitoma, M.D., Ph.D., VBI’s chief medical officer, said: “We believe that a functional cure for HBV is possible, and will require restoration of HBV-specific immunologic control in addition to viral suppression mechanisms. Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV. This combination study represents the first combination of a therapeutic HBV vaccine to restore HBV-immunity with antivirals designed to reduce the levels of HBV surface antigens. We look forward to seeing the outcome of the trial, a milestone that will be meaningful in our collective efforts to provide an effective solution for patients with such a complex and highly infectious virus.”

About BRII-835 (VIR-2218)

BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials. Brii Bio licensed exclusive rights to develop and commercialize VIR-2218 for the greater China territory from Vir in 2020.

In addition to the Phase 2 combination trial with BRII-179 (VBI-2601), VIR-2218 is being evaluated in two ongoing trials: as a monotherapy for HBV, and in combination with pegylated interferon-alpha (PEG-IFN-α). Two additional Phase 2 trials of VIR-2218 are expected to start in 2021.

About BRII-179 (VBI-2601)

VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate, and is designed to target enhanced B-cell and T-cell immunity. VBI-2601 (BRII-179) is being developed in collaboration with Brii Biosciences in the licensed territory of China, Hong Kong, Macau, and Taiwan as part of a potential functional cure for chronic hepatitis B infection.

About Brii Biosciences

Brii Biosciences (Brii Bio) is a multi-national company committed to serving patients’ needs and improving public health by accelerating the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. With operations in the People’s Republic of China and the United States, Brii Bio is poised to serve as a bridge to carry transformative medicines to patients, help create significant growth for our partners and establish an innovation engine to help improve the public health and wellbeing of patients around the world. Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and CNS diseases. For more information, visit www.briibio.com.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. For more information, please visit www.vbivaccines.com.

Vir Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “potential,” “aim,” “could” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-2218, BRII-179, pegylated interferon-alpha, and VIR-3434 (individually or in combination), the expected timing of commencement of clinical trials and availability of clinical data, our goals with respect to the prophylaxis and/or treatment of HBV, the potential ability of our product candidates (individually or in combination with other agents) to functionally cure HBV and change the standard of care, the potential of ESC+ technology to enhance the therapeutic index of VIR-2218, and the potential benefits of Vir’s collaboration with Brii Biosciences and other partners. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials, difficulties in obtaining regulatory approval, difficulties in collaborating with other companies, challenges in accessing manufacturing capacity, clinical site activation rates or clinical trial enrollment rates that are lower than expected, successful development and/or commercialization of alternative product candidates by our competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

VBI Cautionary Statement on Forward-Looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005339/en/

Lisa Beck

Brii Biosciences

[email protected]

Cara Miller

VP, Corporate Communications

[email protected]

+1-415-941-6746

Nicole Anderson

Director, Corporate Communication & IR

[email protected]

(617) 830-3031 x124

KEYWORDS: Macau Singapore Australia Thailand Taiwan Hong Kong Australia/Oceania United States North America Asia Pacific China New Zealand South Korea Canada Massachusetts North Carolina California

INDUSTRY KEYWORDS: Other Health Research General Health Pharmaceutical Oncology Infectious Diseases Clinical Trials Science Biotechnology FDA Other Science Health

MEDIA:

Logo

Logo

Logo

Brii Biosciences, Vir Biotechnology, and VBI Vaccines Announce Initiation of Phase 2 Clinical Trial of BRII-835 (VIR-2218) in Combination with BRII-179 (VBI-2601) for the Treatment of Hepatitis B

– New combination trial of an RNA-targeted therapeutic candidate and an HBV immunotherapeutic candidate aimed at delivering a functional cure for chronic hepatitis B infection –

DURHAM, N.C. & BEIJING & SAN FRANCISCO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Brii Biosciences (Brii Bio), Vir Biotechnology, Inc. (Nasdaq: VIR), and VBI Vaccines Inc. (Nasdaq: VBIV) today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating BRII-835 (VIR-2218), an investigational small interfering ribonucleic acid (siRNA) targeting hepatitis B virus (HBV), in combination with BRII-179 (VBI-2601), an investigational HBV immunotherapeutic, for the treatment of chronic HBV infection. This is the first clinical trial in the field to evaluate the combination of these two HBV mechanisms of action.

The multi-center, randomized, open-label study is designed to evaluate the safety and efficacy of BRII-835 (VIR-2218) compared to the combination of BRII-835 (VIR-2218) and BRII-179 (VBI-2601) with and without interferon-alpha as a co-adjuvant. Both agents have demonstrated proof of mechanism in HBV patients (NCT04507269 BRII-835 China study and ACTRN12619001210167 BRII-179 APEC study). Brii Bio has led the design and implementation of this functional cure proof-of-concept study with the support of VIR and VBI, and is the sponsor of the Phase 2 study (NCT04749368). It will be conducted at sites in Australia, China, Taiwan, Hong Kong Special Administrative Region of China, South Korea, New Zealand, Singapore, and Thailand.

Li Yan, M.D., Ph.D., chief medical officer of Brii Bio, said: “Sustained seroclearance of HBV surface antigen, also known as a functional cure, occurs rarely in the natural history of HBV infection or during the current standard of care treatment. We believe that both viral antigen knockdown with BRII-835 (VIR-2218) and sustained induction of HBV-specific host immune responses by BRII-179 (VBI-2601) are required to remove viral immunosuppression and subsequently break immune tolerance. The combination of these two agents is a step toward developing a functional cure for HBV.”

Phil Pang, M.D., Ph.D., chief medical officer of Vir, said: “This new combination trial represents an important addition to our HBV portfolio approach of combining VIR-2218 with various immunomodulators, including pegylated interferon alpha, VIR-3434 and with a TLR8 agonist, via our previously announced collaboration with Gilead. We look forward to determining if such combinations can stimulate an effective immune response that may result in a finite duration of treatment.”

Francisco Diaz-Mitoma, M.D., Ph.D., VBI’s chief medical officer, said: “We believe that a functional cure for HBV is possible, and will require restoration of HBV-specific immunologic control in addition to viral suppression mechanisms. Data from our previous study suggest BRII-179 (VBI-2601) was able to restimulate both antibody and T cell responses specific to HBV. This combination study represents the first combination of a therapeutic HBV vaccine to restore HBV-immunity with antivirals designed to reduce the levels of HBV surface antigens. We look forward to seeing the outcome of the trial, a milestone that will be meaningful in our collective efforts to provide an effective solution for patients with such a complex and highly infectious virus.”

About BRII-835 (VIR-2218)

BRII-835 (VIR-2218) is an investigational subcutaneously administered HBV-targeting siRNA that has the potential to stimulate an effective immune response and have direct antiviral activity against HBV. It is the first siRNA in the clinic to include Enhanced Stabilization Chemistry Plus (ESC+) technology to enhance stability and minimize off-target activity, which potentially can result in an increased therapeutic index. VIR-2218 is the first asset in the Company’s collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical trials. Brii Bio licensed exclusive rights to develop and commercialize VIR-2218 for the greater China territory from Vir in 2020.

In addition to the Phase 2 combination trial with BRII-179 (VBI-2601), VIR-2218 is being evaluated in two ongoing trials: as a monotherapy for HBV, and in combination with pegylated interferon-alpha (PEG-IFN-α). Two additional Phase 2 trials of VIR-2218 are expected to start in 2021.

About BRII-179 (VBI-2601)

VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate, and is designed to target enhanced B-cell and T-cell immunity. VBI-2601 (BRII-179) is being developed in collaboration with Brii Biosciences in the licensed territory of China, Hong Kong, Macau, and Taiwan as part of a potential functional cure for chronic hepatitis B infection.

About Brii Biosciences

Brii Biosciences (Brii Bio) is a multi-national company committed to serving patients’ needs and improving public health by accelerating the development and delivery of breakthrough medicines through partnerships, best-in-class research and development, and the disruptive application of digital and data insight. With operations in the People’s Republic of China and the United States, Brii Bio is poised to serve as a bridge to carry transformative medicines to patients, help create significant growth for our partners and establish an innovation engine to help improve the public health and wellbeing of patients around the world. Brii Bio is developing treatments for illnesses with significant public health burdens, including infectious diseases, liver diseases, and CNS diseases. For more information, visit www.briibio.com.

About Vir Biotechnology

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.

About VBI Vaccines Inc.

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel. For more information, please visit www.vbivaccines.com.

Vir Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “potential,” “aim,” “could” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Vir’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding the potential benefits of VIR-2218, BRII-179, pegylated interferon-alpha, and VIR-3434 (individually or in combination), the expected timing of commencement of clinical trials and availability of clinical data, our goals with respect to the prophylaxis and/or treatment of HBV, the potential ability of our product candidates (individually or in combination with other agents) to functionally cure HBV and change the standard of care, the potential of ESC+ technology to enhance the therapeutic index of VIR-2218, and the potential benefits of Vir’s collaboration with Brii Biosciences and other partners. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data or results observed during clinical trials, difficulties in obtaining regulatory approval, difficulties in collaborating with other companies, challenges in accessing manufacturing capacity, clinical site activation rates or clinical trial enrollment rates that are lower than expected, successful development and/or commercialization of alternative product candidates by our competitors, changes in expected or existing competition, delays in or disruptions to Vir’s business or clinical trials due to the COVID-19 pandemic, geopolitical changes or other external factors, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir’s filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as required by law, Vir assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

VBI Cautionary Statement on Forward-Looking Information

Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking information within the meaning of Canadian securities laws (collectively, “forward-looking statements”). The Company cautions that such statements involve risks and uncertainties that may materially affect the Company’s results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to, the impact of general economic, industry or political conditions in the United States or internationally; the impact of the ongoing COVID-19 pandemic on our clinical studies, manufacturing, business plan, and the global economy; the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company’s ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company’s products. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company’s filings with the SEC and the Canadian securities authorities, including its Annual Report on Form 10-K filed with the SEC on March 2, 2021, and filed with the Canadian security authorities at sedar.com on March 2, 2021, as may be supplemented or amended by the Company’s Quarterly Reports on Form 10-Q. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. All such forward-looking statements made herein are based on our current expectations and we undertake no duty or obligation to update or revise any forward-looking statements for any reason, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005337/en/

Lisa Beck

Brii Biosciences

[email protected]

Cara Miller

VP, Corporate Communications

[email protected]

+1-415-941-6746

Nicole Anderson

Director, Corporate Communication & IR

[email protected]

(617) 830-3031 x124

KEYWORDS: China United States North America Asia Pacific California North Carolina

INDUSTRY KEYWORDS: Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Logo

Data Theorem Web Secure Earns 2021 Government Security Award

Independent Panel of Judges from Security Industry Honors Web Secure for Automating Analysis and Remediation to Protect Against Modern Web Application Data Breaches

PALO ALTO, Calif.–(BUSINESS WIRE)–
Data Theorem, Inc., a leading provider of modern application security, today announced that its Web Secure AppSec solution has earned a 2021 The Govies Government Security Award from Security Today magazine, the only integrated product and technology magazine reaching the entire security market. The award program honors outstanding government security products in a variety of categories. Data Theorem won the top award in the Application Security awards category.

“It is apparent that the COVID-19 pandemic had very little affect upon product development and deployment in the government security sector,” said Ralph C. Jensen, editor in chief, Security Today magazine. “We appreciate all the manufacturers who labor diligently to ensure security in the government space, including federal, state, local and Native American jurisdictions. We’re pleased to honor these winners and thank all those who participated in this amazing process.”

Web Secure is the industry’s first full-stack application security analyzer that provides vulnerability analysis for modern web applications from the web-layer down to its embedded APIs and cloud resources. This product enables DevOps and security teams to improve web application security testing for issues that have plagued the industry for years by both identifying and helping remediate potential data breaches in modern web applications, also known as Single-Page Applications (SPAs).

1105 Media launched its government security awards program in 2009. In 2011, this successful program became known as The Govies. An independent panel of judges from the security industry selected the top entries and 2021 winners using criteria including Features, Innovation, User Friendliness, Interoperability, Quality, Design, Market Opportunity, Impact in the Security Industry, Technical Advances, and Scalability.

“It is an honor for Web Secure to continue to be recognized with another industry award, this time by Security Today’s independent panel of security experts for its unique design to help customers secure their modern web applications,” said Doug Dooley, Data Theorem COO. “The government sector is an important area of growth for Data Theorem, where we are seeing significant interest due to the benefits of our dynamic and run-time analysis that is fully integrated into the CI/CD process, and enables government agencies to conduct continuous, automated security inspection and remediation of their cloud-native web applications.”

Data Theorem’s broad AppSec portfolio protects organizations from data breaches with application security testing and protection for modern web frameworks, API-driven microservices and cloud resources. Its solutions are powered by its award-winning Analyzer Engine, which leverages a new type of dynamic and run-time analysis that is fully integrated into the CI/CD process, and enables organizations to conduct continuous, automated security inspection and remediation. Data Theorem’s AppSec portfolio secures mobile apps, cloud-driven APIs, and modern web applications.

About 1105 Media’s Infrastructure Solutions Group

1105 Media’s Infrastructure Solutions Group includes several leading industry media brands that provide new product and technology solutions for security professionals: Security Today, securitytoday.com, GovSec, Campus Security & Life Safety, and campuslifesecurity.com. The brands’ print, digital, custom media and research products integrate physical and IT security coverage and provide the smartest, most cost-effective solutions for reaching security decision makers.

About Data Theorem

Data Theorem is a leading provider of modern application security. Its core mission is to analyze and secure any modern application anytime, anywhere. The award-winning Data Theorem Analyzer Engine continuously analyzes APIs, Web, Mobile, and Cloud applications in search of security flaws and data privacy gaps. Data Theorem products help organizations prevent AppSec data breaches. The company has detected more than 1 billion application eavesdropping incidents and currently secures more than 8,000 modern applications for its enterprise customers around the world. Data Theorem is headquartered in Palo Alto, Calif., with offices in New York and Paris. For more information visit www.datatheorem.com.

Data Theorem and TrustKit are trademarks of Data Theorem, Inc. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005294/en/

Dan Spalding

[email protected]

(408) 960-9297

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Security Technology Software Networks Internet

MEDIA:

Logo

HomeServe Enters the Pittsburgh Plumbing and HVAC Market With Acquisition of Mark Allen Plumbing and Heating

HomeServe has acquired 13 locally branded HVAC companies serving customers in six states and the District of Columbia

NORWALK, Conn.–(BUSINESS WIRE)–HomeServe USA (HomeServe), a leading provider of service plans, repair, and installation services for the home, today announced the acquisition of Mark Allen Plumbing and Heating (Mark Allen). Based in Bethel Park, Pennsylvania, a suburb of Pittsburgh, Mark Allen provides plumbing and HVAC services to residential and commercial customers in the greater Pittsburgh area.

Mark Gillece founded the Mark Allen business in 1985 and has served as its leader ever since. He’s grown this business to include a team of 21 skilled trade plumbing and HVAC professionals dedicated to serving their neighbors in and around the Steel City.

“Growing HomeServe’s HVAC and plumbing segment means bringing customer-focused, ethical companies into our business. That’s exactly what we’ve found in Mark Allen Plumbing and Heating,” said Rob DiPietro, Managing Director, HVAC at HomeServe. “Mark Gillece and his team have built an exceptional locally admired business, one that’s well known throughout Pittsburgh. Now with HomeServe, we’ll work together to ensure that reputation and Mark’s legacy endures.”

The entire Mark Allen team keeps customer satisfaction and business ethics at the forefront of what they do. Mark Allen has been an A+ rated Better Business Bureau company for 20 years. In 2019, it was the recipient of the Western Pennsylvania BBB Torch Award for Ethics, which underscores their commitment to doing right by their customers every day.

“When I started Mark Allen decades ago, my vision was to be 100% customer focused. I wanted to deliver the best possible professional experience to all our customers,” noted Mark Gillece. “In looking toward our future, it was critical to me that we find the right partner, one that shares our values and would help us continue our vision while ensuring that the culture within our organization would not change. We found that perfect partner in HomeServe. Partnering with HomeServe will enable us to deliver an even better experience to our customers while leveraging HomeServe’s support to continue to proudly serve the greater Pittsburgh market.”

Mark Allen joins a growing number of Pennsylvania-based companies acquired by HomeServe in recent years. HomeServe’s acquisitions in the Keystone State include: UGI Heating, Cooling and Plumbing, the digital agency Vincodo, and Utility Service Partners, a home repair service plan provider. Leading HVAC, plumbing, and electrical businesses throughout the U.S. interested in exploring the opportunity to join HomeServe should visit the HomeServe Transition website or email Rob DiPietro, Managing Director, HVAC. For more information about HomeServe, visit www.HomeServe.com.

About HomeServe

HomeServe USA Corp. (HomeServe) is a leading provider of home repair and installation solutions serving more than 4.5 million customers across the U.S. and Canada under the HomeServe, Home Emergency Insurance Solutions, Service Line Warranties of America (SLWA), and Service Line Warranties of Canada (SLWC) names.

Since 2003, HomeServe has been protecting homeowners against the expense and inconvenience of water, sewer, electrical, HVAC and other home repair emergencies by providing affordable repair coverage, installations, and quality local service.

As an A+ rated Better Business Bureau Accredited Business, HomeServe is dedicated to being a customer-focused company supplying best-in-class repair plans and other services to consumers directly and through over 1,000 leading municipal, utility and association partners.

HomeServe has teamed up with executive producer, host, and best-selling author Mike Rowe, best known as the creator and host of the hit TV series Dirty Jobs, to work together to provide homeowners expert advice on maintaining, enhancing and protecting their homes. For more information about HomeServe, a Great Place To Work certified winner and recipient of thirty 2020 Stevie Awards for Sales & Customer Service, or to learn more about HomeServe’s affordable repair plans, please go to www.homeserve.com. Connect with HomeServe on Facebook and Twitter @HomeServeUSA. For news and information follow on Twitter @HomeServeUSNews.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005291/en/

Myles Meehan

HomeServe USA

Phone: 203-356-4259

Email: [email protected]

Claire Deneen

Hill+Knowlton Strategies for HomeServe

Phone: 312-255-3134

Email: [email protected]

KEYWORDS: United States North America Pennsylvania Connecticut

INDUSTRY KEYWORDS: Professional Services Other Construction & Property Residential Building & Real Estate Insurance Construction & Property Building Systems

MEDIA:

Logo